December 2024 saw the launch of Dotinurad, a fresh gout medicine that drops uric acid quickly while sparing the liver. It’s especially helpful for people who can’t tolerate older pills like allopurinol or febuxostat. Chinese drug makers are racing ahead: SHR4640 is already waiting for approval, and candidates such as AR882, HP501 and D‑0120 are in late‑stage trials, all showing strong results. Researchers are also betting on “dual‑action” drugs that do more than just flush out uric acid. One example, alulufenate, may both boost uric‑acid excretion and improve insulin resistance, offering hope for gout patients who also have diabetes. Another newcomer, tigulixostat, belongs to a new class of xanthine oxidase inhibitors and aims to match or beat febuxostat’s power while being gentler on the heart. Finally, scientists are targeting the painful flare‑ups themselves. New anti‑inflammatory agents that block IL‑1β, such as canakinumab and anakinra, are proving effective for severe attacks where traditional drugs fall short. As costs fall and evidence grows, these precision medicines could soon become the go‑to options for safer, faster gout relief.
Read moreA wave of fresh discoveries is shaking up the biotech world. Researchers have finally proved that flu‑infected people release wildly different amounts of virus in their breath, explaining why some spread the illness more easily and pointing to smarter prevention tactics. At a massive 4,000‑person conference, scientists presented evidence‑based standards for food‑drug‑cosmetics integration, highlighting the power of large‑scale data. In a clever twist on probiotics, a team engineered Lactobacillus reuteri to carry both an anti‑PD‑L1 antibody and gallium ions, striking tumors on two fronts and offering hope for “cold” cancers that resist treatment. Meanwhile, a new glucose‑lowering drug, mazdutide, showed promise for severe obesity in Chinese patients. The scientific community also launched a live “Research Experiment Talk Show” to help troubleshoot common lab woes like Western blot failures. A Zhejiang University study revealed that type I interferon signals act as a “smart knob” on lung macrophages, balancing antibacterial and anti‑cancer defenses. Junsha Pharmaceutical celebrated two milestones: FDA orphan‑drug status for a gastric‑cancer candidate and IND approval for an eye‑targeted bispecific antibody. Sex‑specific metabolism in T cells was uncovered, showing the enzyme DGAT1’s role under androgen influence, while a smartwatch combined with routine blood tests can now flag insulin resistance years before diabetes appears. Finally, researchers linked the Parkinson’s gene PLA2G6 to the critical communication bridge between the endoplasmic reticulum and mitochondria, shedding light on cellular “logistics” failures in neurodegeneration.
Read moreFrom March 25‑28, 2026, the European Lung Cancer Congress (ELCC) gathered more than 2,000 experts in Copenhagen to unveil the latest advances in lung‑cancer care. Among the highlights were nine original studies led by Chinese researchers, each earning a coveted spot in the Oral Presentation or Late‑Breaking Abstract sessions. One study (LBA‑4) presented the final overall‑survival results of sacituzumab‑tirumotecan, an antibody‑drug conjugate, in patients whose EGFR‑mutated non‑small‑cell lung cancer (NSCLC) had already been treated. The data suggest a meaningful survival benefit over existing options. Another late‑breaking abstract (LBA‑5) explored a one‑time low‑dose CT scan for a broad, non‑high‑risk population, showing a potential reduction in lung‑cancer mortality even among people not traditionally screened. In the oral presentations, the TOP study compared osimertinib alone versus osimertinib combined with chemotherapy for EGFR‑mutant NSCLC that also carries TP53 mutations. The combination arm more than doubled median progression‑free survival to 16.8 months (vs 10.5 months) and boosted response rates without adding serious side‑effects. These Chinese contributions underscore a growing global impact, offering fresh hope for patients with advanced, drug‑resistant lung cancer and pointing toward more personalized, effective treatment pathways.
Read more